NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

By G. Demetri, R. Benjamin, C. Blanke, J. Blay, P. Casali, Haesun Choi, Christopher Corless, M. Debiec-Rychter, R. DeMatteo, D. Ettinger and 19 more. The Journal of the National Comprehensive Cancer Network, 2007

660 citations recorded by the source corpus.

Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/7113a2a3d39201b4fdde967b7c5c3ab1b33fa5b0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. Heikki Joensuu
2. M. Heinrich
3. Christopher Corless

In Pulmonary and Respiratory Medicine

1. M. Heinrich
2. Heikki Joensuu

Citations in the corpus

• Risk stratification of patients diagnosed with gastrointestinal stromal tumor. (2008, background): “025 stomach and small intestine, and they may rarely arise at extragastrointestinal sites such as the omentum or mesentery [4].”
• Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. (2008, background): “These data, as well as a combined mutational meta-analysis of S0033 and EORTC information, were strong enough for the National Comprehensive Cancer Network to recommend, in a nonuniform consensus statement, the use of higher-dose drug for patients with known exon 9 mutations.(23) Final analyses from”